Corbus Pharmaceuticals

OverviewSuggest Edit

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, anabasum, is a novel synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. It is currently being evaluated in four clinical programs: systemic sclerosis, cystic fibrosis, dermatomyositis and systemic lupus erythematosus.

TypePublic
Founded2009
HQNorwood, US
Websitecorbuspharma.com

Latest Updates

Employees (est.) (Dec 2018)77(+64%)
Job Openings27
Share Price (Oct 2019)$4.8

Key People/Management at Corbus Pharmaceuticals

Yuval Cohen

Yuval Cohen

Chief Executive Officer, Director
Mark A. Tepper

Mark A. Tepper

President & Chief Scientific Officer
Barbara White

Barbara White

Chief Medical Officer
Robert Discordia

Robert Discordia

Vice President, Pharmaceutical Development & Manufacturing
Ross Lobell

Ross Lobell

Vice President, Regulatory Affairs
Show more

Corbus Pharmaceuticals Office Locations

Corbus Pharmaceuticals has an office in Norwood
Norwood, US (HQ)
100 River Ridge Dr #103
Show all (1)

Corbus Pharmaceuticals Financials and Metrics

Corbus Pharmaceuticals Revenue

USD

Net income (Q2, 2019)

2.2m

EBIT (Q2, 2019)

1.7m

Market capitalization (16-Oct-2019)

310.3m

Closing stock price (16-Oct-2019)

4.8

Cash (30-Jun-2019)

73.2m

EV

237.4m
Corbus Pharmaceuticals's current market capitalization is $310.3 m.
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018

General and administrative expense

3.6m6.5m9.0m13.0m

R&D expense

5.9m15.4m26.0m48.6m

Operating expense total

9.5m21.9m35.0m61.6m

EBIT

(8.9m)(20.0m)(32.6m)(56.7m)
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

General and administrative expense

969.1k790.6k1.1m1.0m1.8m2.4m1.9m2.1m3.1m3.0m3.2m6.6m5.2m

R&D expense

1.7m1.6m2.2m3.6m4.3m6.4m5.8m5.6m9.8m10.3m12.8m21.8m22.2m

Operating expense total

2.7m2.4m3.3m4.6m6.1m8.7m7.6m7.8m12.8m13.2m16.0m28.4m27.4m

EBIT

(2.6m)(2.3m)(2.9m)(4.2m)(5.3m)(7.5m)(7.3m)(7.0m)(11.9m)(12.4m)(14.9m)(26.5m)1.7m
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(8.9m)(20.0m)(32.4m)(55.7m)

Depreciation and Amortization

43.9k87.7k255.7k493.9k

Accounts Payable

972.2k1.9m(885.8k)3.9m

Cash From Operating Activities

(4.6m)(13.6m)(27.8m)(30.1m)
USDY, 2019

EV/EBIT

139.2 x

EV/CFO

-39.1 x

Financial Leverage

1.8 x
Show all financial metrics

Corbus Pharmaceuticals Online and Social Media Presence

Embed Graph

Corbus Pharmaceuticals News and Updates

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corbus Pharmaceuticals Holdings, Inc. - CRBP

NEW YORK, March 13, 2019 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Corbus Pharmaceuticals Holdings, Inc. ("Corbus" or the "Company") (NASDAQ: CRBP). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ...

Corbus Pharmaceuticals to Present at the Oppenheimer 29th Annual Healthcare Conference

- Presentation with live audio webcast on Tuesday, March 19, 2019 at 2:10 p.m. ET-

Corbus Pharmaceuticals Announces Closing of $40 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares

Norwood, MA, Jan. 30, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company), a clinical stage drug development company with the industry’s leading pipeline focused on treating inflammatory and fibrotic diseases through the endocannabinoid system p…

Corbus Pharmaceuticals Announces Strategic Collaboration with Kaken Pharmaceutical Co., Ltd. to Develop and Commercialize Lenabasum in Japan for Systemic Sclerosis and Dermatomyositis

Norwood, MA, and Tokyo, Japan, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”) announced today that they have entered into a strategic collaboration with Kaken Pharmaceutical Co., Ltd. (“Kaken”) for the development and commercializ…

Corbus Pharmaceuticals Announces Issuance of Composition of Matter Patent Related to Lenabasum

Norwood, MA, Dec. 18, 2018 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage drug development company with the industry’s leading pipeline focused on treating inflammatory and fibrotic diseases by targeting the endocannabinoid sy…

Corbus Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update

Norwood, MA, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage drug development company with the industry leading pipeline focused on treating inflammatory and fibrotic diseases through the endocannabinoid system (“…
Show more

Corbus Pharmaceuticals Blogs

Corbus Pharmaceuticals Announces Presentation of Three Abstracts and New Lenabasum Data at 2019 ACR Annual Meeting

New lenabasum open-label extension study interim data in systemic sclerosis and dermatomyositis to be presented Systemic sclerosis is a rare autoimmune disease affecting ~200,000 people in the U.S., EU and Japan and has the highest mortality rate among the systemic autoimmune diseases Dermatomyosit…

Corbus Pharmaceuticals Reports 2019 Second Quarter Financial Results and Provides Clinical and Corporate Updates

Clinical development of lenabasum on target for 2020 data readouts in lead indications systemic sclerosis and cystic fibrosis; diseases affect ~270,000 people total in U.S., EU and Japan CRB-4001 on course to start Phase 1 study in 2019 as a candidate for NASH Proprietary platform generates first …

Corbus Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2019 Operational and Financial Results on August 8, 2019

- Company to host conference call and webcast on Thursday, August 8 at 8:30 a.m. ET - Norwood, MA, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company), today announced that the Company will host a conference call and live audio webcas…

Corbus Pharmaceuticals to Host 2019 R&D Day in New York City

- R&D Day to be live video webcasted on Friday, June 21st at 10:00 AM ET - Norwood, MA, June 17, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”) today announced that it will host a Research & Development Day (R&D Day) for an…

Lenabasum Open-Label Extension Data to be Presented at EULAR 2019 Continue to Show a Favorable Safety Profile and Improvement in Efficacy Outcomes in Systemic Sclerosis and Dermatomyositis Phase 2 Studies

ACR CRISS score remains ≥ 0.95 (95%) at 21 months in systemic sclerosis open-label extension (OLE) study CDASI activity score reaches -21.8 points at 16 months in dermatomyositis OLE study 81% systemic sclerosis subjects remain on lenabasum in the OLE ≥ 21 months; 90% dermatomyositis subjects rem…

Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in June

Norwood, MA, May 29, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company focused on treating inflammatory and fibrotic diseases by targeting the endocannabinoid system, today announced that Yuval Cohe…
Show more

Corbus Pharmaceuticals Frequently Asked Questions

  • When was Corbus Pharmaceuticals founded?

    Corbus Pharmaceuticals was founded in 2009.

  • Who are Corbus Pharmaceuticals key executives?

    Corbus Pharmaceuticals's key executives are Yuval Cohen, Mark A. Tepper and Barbara White.

  • How many employees does Corbus Pharmaceuticals have?

    Corbus Pharmaceuticals has 77 employees.

  • Who are Corbus Pharmaceuticals competitors?

    Competitors of Corbus Pharmaceuticals include XOMA, Moderna Therapeutics and Bristol-Myers Squibb.

  • Where is Corbus Pharmaceuticals headquarters?

    Corbus Pharmaceuticals headquarters is located at 100 River Ridge Dr #103, Norwood.

  • Where are Corbus Pharmaceuticals offices?

    Corbus Pharmaceuticals has an office in Norwood.

  • How many offices does Corbus Pharmaceuticals have?

    Corbus Pharmaceuticals has 1 office.